• | Revenue of $184.1 million and non-GAAP earnings per share of $0.13 met guidance |
• | 2014 non-GAAP operating expenses at a 15-year low |
• | 2014 non-GAAP earnings per share increased 33% year-over-year |
• | Free cash flow increased by $19 million sequentially |
• | Announced a $4 billion merger with Spansion that is expected to achieve $135 million in annual cost synergies over three years |
NON-GAAP | GAAP | ||||||||||||||||||||||
Q4 2014 | Q3 2014 | Q4 2013 | Q4 2014 | Q3 2014 | Q4 2013 | ||||||||||||||||||
Revenue | $184,097 | $187,516 | $167,776 | $184,097 | $187,516 | $167,776 | |||||||||||||||||
Gross margin | 52.4 | % | 53.5 | % | 51.0 | % | 50.9 | % | 51.7 | % | 45.6 | % | |||||||||||
Pretax margin | 12.6 | % | 15.0 | % | 9.4 | % | 2.7 | % | 7.4 | % | -7.0 | % | |||||||||||
Net income (loss) | $22,056 | $26,538 | $14,992 | $3,503 | $12,840 | $(14,209) | |||||||||||||||||
Diluted EPS (loss per share) | $0.13 | $0.16 | $0.09 | $0.02 | $0.08 | $0.09 | |||||||||||||||||
NON-GAAP | GAAP | ||||||||||||||
FY 2014 | FY 2013 | FY 2014 | FY 2013 | ||||||||||||
Revenue | $725,497 | $722,693 | $725,497 | $722,693 | |||||||||||
Gross margin | 52.6 | % | 52.2 | % | 50.1 | % | 46.9 | % | |||||||
Pretax margin | 12.6 | % | 9.1 | % | 2.1 | % | -7.7 | % | |||||||
Net income (loss) | $87,291 | $63,221 | $17,936 | $(48,241) | |||||||||||
Diluted EPS (loss per share) | $0.52 | $0.39 | $0.11 | $(0.32) | |||||||||||
THREE MONTHS ENDED | |||||||||||||||||
Dec. 28, | Sept. 28, | Dec. 29, | Sequential | Year-over- | |||||||||||||
Business Unit | 2014 | 2014 | 2013 | Change | Year Change | ||||||||||||
PSD1 | $70,433 | $68,750 | $67,746 | 2 | % | 4 | % | ||||||||||
MPD1 | $88,803 | $92,179 | $79,890 | -4 | % | 11 | % | ||||||||||
DCD1 | $17,709 | $19,091 | $16,482 | -7 | % | 7 | % | ||||||||||
ETD1, 2 | $7,152 | $7,496 | $3,658 | -5 | % | 96 | % | ||||||||||
Total | $184,097 | $187,516 | $167,776 | -2 | % | 10 | % | ||||||||||
Geographic | |||||||||||||||||
China and ROW | 60 | % | 60 | % | 64 | % | 0 | % | -6 | % | |||||||
Americas | 16 | % | 17 | % | 14 | % | -6 | % | 14 | % | |||||||
Europe | 14 | % | 14 | % | 12 | % | 0 | % | 17 | % | |||||||
Japan | 10 | % | 9 | % | 10 | % | 11 | % | 0 | % | |||||||
Total | 100 | % | 100 | % | 100 | % | 0 | % | 0 | % | |||||||
Channel | |||||||||||||||||
Distribution | 71 | % | 68 | % | 69 | % | 4 | % | 3 | % | |||||||
Direct | 29 | % | 32 | % | 31 | % | -9 | % | -6 | % | |||||||
Total | 100 | % | 100 | % | 100 | % | 0 | % | 0 | % | |||||||
1. | PSD, Programmable Systems Division; DCD, Data Communications Division; MPD, Memory Products Division. |
2. | ETD, Emerging Technologies Division includes businesses outside our core semiconductor businesses outlined in Footnote 1. Includes subsidiaries AgigA Tech Inc., Deca Technologies Inc., and our foundry business unit. |
TWELVE MONTHS ENDED | ||||||||||
Dec. 28 | Dec. 29 | Year-over- | ||||||||
Business Unit | 2014 | 2013 | Year Change | |||||||
PSD1 | $283,206 | $292,707 | -3 | % | ||||||
MPD1 | $347,903 | $338,986 | 3 | % | ||||||
DCD1 | $70,378 | $79,410 | -11 | % | ||||||
ETD1, 2 | $24,010 | $11,590 | 107 | % | ||||||
Total | $725,497 | $722,693 | 0.4 | % | ||||||
Geographic | ||||||||||
China and ROW | 61 | % | 66 | % | -8 | % | ||||
Americas | 16 | % | 14 | % | 14 | % | ||||
Europe | 14 | % | 11 | % | 27 | % | ||||
Japan | 9 | % | 9 | % | 0 | % | ||||
Total | 100 | % | 100 | % | 0 | % | ||||
Channel | ||||||||||
Distribution | 69 | % | 73 | % | -5 | % | ||||
Direct | 31 | % | 27 | % | 15 | % | ||||
Total | 100 | % | 100 | % | 0 | % | ||||
1. | PSD, Programmable Systems Division; DCD, Data Communications Division; MPD, Memory Products Division. |
2. | ETD, Emerging Technologies Division includes businesses outside our core semiconductor businesses outlined in Footnote 1. Includes subsidiaries AgigA Tech Inc., Deca Technologies Inc., and our foundry business unit. |
• | Join the Cypress Developer Community. |
• | Follow @CypressSemi on Twitter. |
• | Visit us on Facebook and LinkedIn. |
• | Watch Cypress videos on our Video Library or YouTube. |
December 28, | December 29, | ||||
2014 | 2013 | ||||
ASSETS | |||||
Cash, cash equivalents and short-term investments | $118,812 | $104,462 | |||
Accounts receivable, net | 75,984 | 81,084 | |||
Inventories, net (a) | 88,227 | 100,612 | |||
Property, plant and equipment, net | 237,763 | 258,585 | |||
Goodwill and other intangible assets, net | 99,615 | 106,523 | |||
Other assets | 122,880 | 113,707 | |||
Total assets | $743,281 | $764,973 | |||
LIABILITIES AND EQUITY | |||||
Accounts payable | $42,678 | $47,893 | |||
Deferred margin on sales to distributors | 95,187 | 122,578 | |||
Income tax liabilities | 21,494 | 29,001 | |||
Other liabilities | 155,057 | 159,866 | |||
Long-term revolving credit facility | 227,000 | 227,000 | |||
Total liabilities | 541,416 | 586,338 | |||
Total Cypress stockholders' equity | 208,320 | 183,109 | |||
Noncontrolling interest | (6,455 | ) | (4,474 | ) | |
Total equity | 201,865 | 178,635 | |||
Total liabilities and equity | $743,281 | $764,973 | |||
(a) Inventories include $2.0 million and $3.2 million of capitalized inventories related to stock-based compensation expense, as of December 28, 2014 and December 29, 2013, respectively. | |||||
Three Months Ended | Twelve Months Ended | ||||||||||||||||||
December 28, | September 28, | December 29, | December 28, | December 29, | |||||||||||||||
2014 | 2014 | 2013 | 2014 | 2013 | |||||||||||||||
Revenues | $ | 184,097 | $ | 187,516 | $ | 167,776 | $ | 725,497 | $ | 722,693 | |||||||||
Cost of revenues | 90,395 | 90,633 | 91,328 | 361,820 | 384,121 | ||||||||||||||
Gross margin | 93,702 | 96,883 | 76,448 | 363,677 | 338,572 | ||||||||||||||
Operating expenses: | |||||||||||||||||||
Research and development | 39,677 | 38,626 | 42,343 | 164,560 | 190,906 | ||||||||||||||
Selling, general and administrative | 37,746 | 41,119 | 43,623 | 163,488 | 182,671 | ||||||||||||||
Acquisition costs and amortization of acquisition-related intangibles | 8,558 | 1,701 | 1,850 | 13,936 | 7,833 | ||||||||||||||
Restructuring charges | 72 | (238 | ) | (469 | ) | (1,180 | ) | 15,357 | |||||||||||
Loss on divestiture | — | — | — | — | — | ||||||||||||||
Total operating expenses, net | 86,053 | 81,208 | 87,347 | 340,804 | 396,767 | ||||||||||||||
Operating income (loss) | 7,649 | 15,675 | (10,899 | ) | 22,873 | (58,195 | ) | ||||||||||||
Interest and other income, net | (2,759 | ) | (1,890 | ) | (1,437 | ) | (7,528 | ) | 348 | ||||||||||
Income (loss) before income taxes | 4,890 | 13,785 | (12,336 | ) | 15,345 | (57,847 | ) | ||||||||||||
Income tax provision (benefit) | (1,814 | ) | (1,231 | ) | (2,210 | ) | 1,173 | 7,761 | |||||||||||
Income (loss), net of taxes | 3,076 | 12,554 | (14,546 | ) | 16,518 | (50,086 | ) | ||||||||||||
Adjust for net loss attributable to noncontrolling interest | 426 | 286 | 337 | 1,418 | 1,845 | ||||||||||||||
Net Income (loss) attributable to Cypress | $ | 3,502 | $ | 12,840 | $ | (14,209 | ) | $ | 17,936 | $ | (48,241 | ) | |||||||
Net Income (loss) per share attributable to Cypress: | |||||||||||||||||||
Basic | $ | 0.02 | $ | 0.08 | $ | (0.09 | ) | $ | 0.11 | $ | (0.31 | ) | |||||||
Diluted | $ | 0.02 | $ | 0.08 | $ | (0.09 | ) | $ | 0.11 | $ | (0.31 | ) | |||||||
Cash dividend declared per share | $ | 0.11 | $ | 0.11 | $ | 0.11 | $ | 0.44 | $ | 0.44 | |||||||||
Shares used in net income (loss) per share calculation: | |||||||||||||||||||
Basic | 161,864 | 159,759 | 151,580 | 159,031 | 148,558 | ||||||||||||||
Diluted | 169,148 | 166,481 | 151,580 | 169,122 | 148,558 | ||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||||||||||||||||||
December 28, | % of | September 28, | % of | December 29, | % of | December 28, | % of | December 29, | % of | |||||||||||||||||||||||||
2014 | Revenue | 2014 | Revenue | 2013 | Revenue | 2014 | Revenue | 2013 | Revenue | |||||||||||||||||||||||||
GAAP gross margin | $93,702 | 50.9 | % | $96,883 | $76,448 | $363,677 | $338,572 | 46.8 | % | |||||||||||||||||||||||||
Stock-based compensation expense | 2,759 | 1.5 | % | 3,766 | 3,088 | 13,209 | 12,789 | 1.8 | % | |||||||||||||||||||||||||
Acquisition-related expense | 22 | — | % | — | 5,562 | (86 | ) | 24,805 | 3.4 | % | ||||||||||||||||||||||||
Changes in value of deferred compensation plan | (44 | ) | — | % | 4 | 136 | 427 | 854 | 0.2 | % | ||||||||||||||||||||||||
Impairment of assets and other | — | — | % | (303 | ) | 269 | 4,489 | 241 | — | % | ||||||||||||||||||||||||
Non-GAAP gross margin | $96,439 | 52.4 | % | $100,350 | $85,503 | $381,716 | $377,261 | 52.2 | % | |||||||||||||||||||||||||
GAAP research and development expenses | $39,677 | $38,626 | $42,343 | $164,560 | $190,906 | |||||||||||||||||||||||||||||
Stock-based compensation expense | (2,553 | ) | (2,089 | ) | (7,356 | ) | (16,187 | ) | (26,042 | ) | ||||||||||||||||||||||||
Acquisition-related expense | — | — | — | — | (252 | ) | ||||||||||||||||||||||||||||
Changes in value of deferred compensation plan | 128 | (13 | ) | (282 | ) | (793 | ) | (1,744 | ) | |||||||||||||||||||||||||
Impairment of assets, restructuring and other | (252 | ) | (231 | ) | 1,368 | (482 | ) | (1,104 | ) | |||||||||||||||||||||||||
Non-GAAP research and development expenses | $37,000 | $36,293 | $36,073 | $147,098 | $161,764 | |||||||||||||||||||||||||||||
GAAP selling, general and administrative expenses | $46,376 | $41,119 | $46,623 | $176,244 | $182,671 | |||||||||||||||||||||||||||||
Stock-based compensation expense | (1,436 | ) | (6,427 | ) | (10,432 | ) | (20,774 | ) | (34,187 | ) | ||||||||||||||||||||||||
Acquisition-related expense | (8,602 | ) | — | (148 | ) | (14,330 | ) | (1,168 | ) | |||||||||||||||||||||||||
Legal and other | (1,330 | ) | (1,330 | ) | ||||||||||||||||||||||||||||||
Non-cash compensation | — | — | — | — | ||||||||||||||||||||||||||||||
Changes in value of deferred compensation plan | 229 | (24 | ) | (607 | ) | (1,855 | ) | (3,795 | ) | |||||||||||||||||||||||||
Impairment of assets, restructuring and other | (72 | ) | 64 | (244 | ) | (97 | ) | |||||||||||||||||||||||||||
(Gain) loss on divestiture | — | — | — | — | ||||||||||||||||||||||||||||||
Non-GAAP selling, general and administrative expenses | $35,165 | $34,732 | $35,192 | $137,858 | $143,521 | |||||||||||||||||||||||||||||
GAAP operating income (loss) | $7,649 | $15,675 | ($10,899 | ) | $22,873 | ($58,195 | ) | |||||||||||||||||||||||||||
Stock-based compensation expense | 6,748 | 12,282 | 20,877 | 50,170 | 73,020 | |||||||||||||||||||||||||||||
Acquisition-related expense | 8,622 | 1,701 | 7,558 | 14,244 | 34,056 | |||||||||||||||||||||||||||||
Non-cash compensation | — | — | — | — | — | |||||||||||||||||||||||||||||
Changes in value of deferred compensation plan | (402 | ) | 41 | 1,026 | 3,075 | 6,393 | ||||||||||||||||||||||||||||
Impairment of assets, restructuring and other | 328 | (374 | ) | (1,324 | ) | 5,067 | 17,152 | |||||||||||||||||||||||||||
Non-GAAP operating income | $22,945 | $29,235 | $17,238 | $96,759 | $72,426 | |||||||||||||||||||||||||||||
GAAP operating income (loss) | $4,890 | 2.7 | % | $13,785 | 7.4 | % | ($12,336 | ) | (7.4 | %) | $15,345 | 2.1 | % | ($57,847 | ) | (8.0 | %) | |||||||||||||||||
Stock-based compensation expense | 6,748 | 3.7 | % | 12,282 | 6.5 | % | 20,877 | 12.4 | % | 50,170 | 6.9 | % | 73,020 | 10.1 | % | |||||||||||||||||||
Acquisition-related expense | 8,622 | 4.7 | % | 1,701 | 0.9 | % | 7,558 | 4.5 | % | 14,244 | 2.0 | % | 34,056 | 4.7 | % | |||||||||||||||||||
Changes in value of deferred compensation plan | (1,048 | ) | (0.6 | )% | 288 | 0.2 | % | 1,026 | 0.6 | % | 61 | — | % | 22 | — | % | ||||||||||||||||||
Legal and other | 1,330 | 0.7 | % | — | — | % | — | — | % | 1,330 | 0.2 | % | — | — | % | |||||||||||||||||||
Tax related and other items | (618 | ) | (0.3 | )% | (967 | ) | (0.5 | )% | (633 | ) | (0.4 | )% | (263 | ) | — | % | (2,267 | ) | (0.3 | )% | ||||||||||||||
Investment related losses | 1,495 | 0.8 | % | — | — | — | % | 1,495 | 0.2 | % | — | — | % | |||||||||||||||||||||
Losses from equity method investment | 1,403 | 0.7 | % | 1,386 | 0.7 | % | 632 | 0.4 | % | 5,068 | 0.7 | % | 1,877 | 0.3 | % | |||||||||||||||||||
Impairment of assets, restructuring and other | 327 | 0.2 | % | (374 | ) | (0.1 | )% | (1,324 | ) | (0.8 | )% | 3,737 | 0.5 | % | 17,152 | 2.4 | % | |||||||||||||||||
Non-GAAP operating income | $23,149 | 12.6 | % | $28,101 | 15.1 | % | $15,800 | 9.3 | % | $91,187 | 12.6 | % | $66,013 | 9.2 | % | |||||||||||||||||||
GAAP net income (loss) attributable to Cypress | $3,503 | $13,785 | ($13,577 | ) | $17,936 | ($48,241 | ) | |||||||||||||||||||||||||||
Stock-based compensation expense | 6,748 | 12,282 | 20,877 | 50,170 | 73,020 | |||||||||||||||||||||||||||||
Acquisition-related expense | 8,622 | 1,701 | 7,558 | 14,244 | 11,514 | |||||||||||||||||||||||||||||
Non-cash compensation | — | — | — | — | ||||||||||||||||||||||||||||||
Changes in value of deferred compensation plan | (1,048 | ) | 288 | (535 | ) | 61 | 22 | |||||||||||||||||||||||||||
Impairment of assets and other | 327 | (137 | ) | (854 | ) | |||||||||||||||||||||||||||||
Legal and other | 1,330 | 1,330 | ||||||||||||||||||||||||||||||||
Impairment of assets, restructuring and other | — | (238 | ) | (470 | ) | 3,737 | 39,694 | |||||||||||||||||||||||||||
Tax and tax-related items | (324 | ) | (966 | ) | 1,065 | (6,750 | ) | (14,665 | ) | |||||||||||||||||||||||||
Investment-related gains/losses | 1,495 | 1,386 | 930 | 1,495 | ||||||||||||||||||||||||||||||
Patent license fee | — | — | — | — | ||||||||||||||||||||||||||||||
Loss from equity method investment | 1,403 | 5,068 | 1,877 | |||||||||||||||||||||||||||||||
(Gain) loss on divestiture and expenses | — | — | — | — | ||||||||||||||||||||||||||||||
Non-GAAP net income attributable to Cypress | $22,056 | $28,101 | $14,994 | $87,291 | $63,221 | |||||||||||||||||||||||||||||
GAAP net income (loss) per share attributable to Cypress - diluted | $0.02 | $0.08 | ($0.09 | ) | $0.11 | ($0.32 | ) | |||||||||||||||||||||||||||
Stock-based compensation expense | 0.04 | 0.07 | 0.13 | 0.30 | 0.45 | |||||||||||||||||||||||||||||
Acquisition-related expense | 0.05 | 0.01 | 0.05 | 0.08 | 0.21 | |||||||||||||||||||||||||||||
Change in value of deferred compensation plan | (0.01 | ) | — | (0.01 | ) | 0.02 | 0.01 | |||||||||||||||||||||||||||
Tax and tax-related items | — | (0.01 | ) | 0.01 | (0.04 | ) | (0.08 | ) | ||||||||||||||||||||||||||
Impairment of assets, restructuring and other | — | — | (0.01 | ) | 0.02 | 0.10 | ||||||||||||||||||||||||||||
Legal and other | 0.01 | 0.01 | ||||||||||||||||||||||||||||||||
Investment-related gains/losses | 0.01 | 0.01 | 0.01 | 0.01 | (0.01 | ) | ||||||||||||||||||||||||||||
Non-GAAP share count adjustment | — | — | (0.01 | ) | — | 0.02 | ||||||||||||||||||||||||||||
Loss from equity method investment | 0.01 | 0.01 | 0.03 | 0.01 | ||||||||||||||||||||||||||||||
Non-GAAP net income per share attributable to Cypress - diluted | $0.13 | $0.16 | $0.09 | $0.39 | $0.55 | |||||||||||||||||||||||||||||
(a) Refer to the accompanying "Notes to Non-GAAP Financial Measures" for a detailed discussion of management's use of non-GAAP financial measures. | ||||||||||||||||||||||||||||||||||
Three Months Ended | Twelve Months Ended | ||||||||||||||||||
December 28, | September 28, | December 29, | December 28 | December 29, | |||||||||||||||
2014 | 2014 | 2013 | 2014 | 2013 | |||||||||||||||
Selected Cash Flow Data (Preliminary): | |||||||||||||||||||
Net cash provided by operating activities | $25,514 | $8,322 | $20,171 | $103,336 | $66,696 | ||||||||||||||
Net cash provided by (used in) investing activities | ($13,736 | ) | ($11,173 | ) | $569 | ($42,156 | ) | $1,139 | |||||||||||
Net cash provided by (used in) financing activities | ($13,126 | ) | $6,501 | ($11,276 | ) | ($43,453 | ) | ($45,024 | ) | ||||||||||
Other Supplemental Data (Preliminary): | |||||||||||||||||||
Capital expenditures | $3,769 | $5,800 | $8,750 | $20,947 | $36,627 | ||||||||||||||
Depreciation | $10,013 | $10,093 | $9,436 | $39,724 | $39,572 | ||||||||||||||
Payment of dividend | $17,728 | $17,413 | $16,578 | $69,248 | $64,819 | ||||||||||||||
Dividend paid per share | $0.11 | $0.11 | $0.11 | $0.11 | $0.44 | ||||||||||||||
Dividend yield per share (a) | 3.0 | % | 4.4 | % | 4.3 | % | 3.0 | % | 4.3 | % | |||||||||
Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||||||||||||||||||
December 28, | September 28, | December 29, | December 28, | December 29, | |||||||||||||||||||||||||||||||||||
2014 | 2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||||||||||||||
GAAP | Non-GAAP | GAAP | Non-GAAP | GAAP | Non-GAAP | GAAP | Non-GAAP | GAAP | Non-GAAP | ||||||||||||||||||||||||||||||
Net income (loss) attributable to Cypress | $3,502 | $22,056 | ($8,358 | ) | $22,015 | ($14,209 | ) | $14,992 | ($46,364 | ) | $63,221 | ($46,364 | ) | $63,221 | |||||||||||||||||||||||||
Weighted-average common shares outstanding (basic) | 161,864 | 161,864 | 149,679 | 149,679 | 151,580 | 151,580 | 148,558 | 148,558 | 148,558 | 148,558 | |||||||||||||||||||||||||||||
Effect of dilutive securities: | |||||||||||||||||||||||||||||||||||||||
Stock options, unvested restricted stock and other | 7,284 | 8,892 | — | 12,525 | — | 14,224 | — | 12,954 | — | 12,954 | |||||||||||||||||||||||||||||
Weighted-average common shares outstanding for diluted computation | $169,148 | $170,756 | $149,679 | $162,204 | $151,580 | $165,804 | $148,558 | $161,512 | $148,558 | $161,512 | |||||||||||||||||||||||||||||
Net income (loss) per share attributable to Cypress - basic | $0.02 | $0.14 | ($0.06 | ) | $0.15 | ($0.09 | ) | $0.10 | ($0.31 | ) | $0.43 | ($0.31 | ) | $0.43 | |||||||||||||||||||||||||
Net income (loss) per share attributable to Cypress - diluted | $0.02 | $0.13 | ($0.06 | ) | $0.14 | ($0.09 | ) | $0.09 | ($0.31 | ) | $0.39 | ($0.31 | ) | $0.39 | |||||||||||||||||||||||||
December 28, | September 28, | December 29, | December 28, | December 29, | |||||||||||||||||||||||||||||||||||
2014 | 2014 | 2013 | 2014 | 2013 | |||||||||||||||||||||||||||||||||||
Average stock price for the period ended | $ | 10.77 | $ | 10.54 | $ | 9.45 | $ | 10.18 | $ | 10.59 | |||||||||||||||||||||||||||||
Common stock outstanding at period end (in thousands) | 163,013 | 161,178 | 153,214 | 163,013 | 153,214 | ||||||||||||||||||||||||||||||||||
• | Gross margin |
• | Research and development expenses |
• | Selling, general and administrative expenses |
• | Operating income (loss) |
• | Net income (loss) |
• | Diluted net income (loss) per share |